SAN CLEMENTE, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners ...
FDA clearance supported by a clinical study (n=67) and demonstrated treatment safety and efficacy utilizing SUPERB™, 97% of the treated participants in the trial showed improvement in the appearance ...
SAN CLEMENTE, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced ...
SAN CLEMENTE, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced ...
FDA clearance supported by highly compelling clinical study results demonstrating 93% of subjects treated arms were “improved” or “very much improved” in appearance, following treatment utilizing ...